US 7,507,408 B2
	Anti hepatitis C virus antibody and uses thereof
Christian Reiter, Karsfeld (Germany); Francois Habersetzer, Illkirch-Graffenstaden (France); Anne Fournillier, Lyons (France); Christian Trepo, Bron (France); Claude Desgranges, Paris (France); and Genevieve Inchauspe, Lyons (France)
Assigned to Genmab A/S, Copenhagen-K (Denmark)
Filed on Oct. 25, 2004, as Appl. No. 10/972,296.
Application 10/972296 is a division of application No. 09/744176, filed on Jun. 18, 2001, granted, now 6,951,646.
Claims priority of application No. 98113595 (EP), filed on Jul. 21, 1998; and application No. PCT/EP99/05173 (EP), filed on Jul. 20, 1999.
Prior Publication US 2006/0153833 A1, Jul. 13, 2006
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/29 (2006.01); A61K 39/42 (2006.01); A61K 39/12 (2006.01); C12Q 1/70 (2006.01); G01N 35/53 (2006.01)

U.S. Cl. 424—149.1  [424/141.1; 424/134.1; 424/135.1; 424/139.1; 424/142.1]

5 Claims

1. An isolated antibody, wherein said antibody specifically recognizeds the same conformation-dependent epitope of Hepatitis C Virus (HCV) E2 present on HCV genotypes 1a, 1b, 2, 3a and 4 as that bound by an antibody comprising the complementarity determining regions (CDR) of SEQ ID NO: 2 and the CDRs of SEQ ID NO: 4, and precipitates covalently or non-covalently associated E2/E1 complexes.